In Phase C, members will acquire ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Members will get treatment till ailment progression or perhaps the members are not able to tolerate the study drugs. 88 These preclinical studies provide paradigms for potential clinical trials in AML, https://josephn777bnx0.blogpixi.com/profile